



癌症-临床前 (Cancer)







癌症

免疫治疗与细胞治疗

bioxcell.com





癌症 - 临床前研究用体内抗体 (免疫治疗, 细胞与基因治疗)



靶标	反应种属	应用类型	克隆号	InVivoMab	InVivoPlus
4-1BB (CD137)	mouse	<i>in vivo</i> activation of 4-1BB	LOB12.3	BE0169	BP0169
4-1BB (CD137)	mouse	<i>in vivo</i> and <i>in vitro</i> 4-1BB stimulation	3H3	BE0239	BP0239
4-1BB (CD137)	mouse	<i>in vitro</i> 4-1BB blockade, FC	17B5	BE0296	
4-1BBL (CD137L)	mouse	<i>in vivo</i> 4-1BBL blockade	TKS-1	BE0110	
B7-1 (CD80)	mouse	<i>in vivo</i> B7-1 blockade, Affinity chromatography	1G10	BE0134	
BTLA (CD272)	mouse	<i>in vivo</i> BTLA stimulation, <i>in vivo</i> BTLA blockade	6A6	BE0132	
BTLA (CD272)	mouse	<i>in vivo</i> and <i>in vitro</i> stimulation of BTLA, FC	PK18.6	BE0153	
BTLA (CD272)	mouse	<i>in vivo</i> BTLA blockade, <i>in vitro</i> T cell stimulation/activation, FC	PJ196	BE0196	
CD19	mouse	<i>in vivo</i> B cell depletion, <i>in vivo</i> CD19 neutralization, <i>in vitro</i> B cell negative selection, FC	1D3	BE0150	
CD19	human	FC, Functional assays, IF, Chimeric antigen receptor construction	4G7	BE0281	
CD20	mouse	<i>in vivo</i> B cell depletion, WB	MB20-11	BE0356	
CD20	human/monkey	<i>in vivo</i> B cell depletion in hCD20 Tg mice, IHC-F, IP, FC	2H7	BE0276	
CD20	mouse	FC, WB	AISB12	BE0302	
CD24	mouse	<i>in vivo</i> administration, IHC-F, IHC-P, IF, FC	M1/69	BE0360	
CD27	mouse	<i>in vivo</i> CD27 stimulation, <i>in vitro</i> CD27 stimulation, IP, FC	RM27-3E5	BE0348	
CD28	mouse	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD28 blockade	37.51	BE0015-1	
CD28	mouse	<i>in vitro</i> T cell stimulation/activation	PV-1	BE0015-5	
CD28	human	<i>in vitro</i> T cell stimulation/activation	9.3	BE0248	
CD28	human/monkey	<i>in vitro</i> T cell stimulation/activation, FC, IHC-F, IP	CD28.2	BE0291	
CD28	mouse	<i>in vivo</i> and <i>in vitro</i> T cell stimulation/activation	D665	BE0328	
CD38	mouse	<i>in vivo</i> and <i>in vitro</i> CD38 stimulation, <i>in vitro</i> B cell activation, IF	NIMR5	BE0317	
CD40	mouse	<i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation	FGK4.5/FGK45	BE0016-2	BP0016-2
CD40L (CD154)	mouse	<i>in vivo</i> and <i>in vitro</i> blocking of CD40/CD40L signaling	MR-1	BE0017-1	BP0017-1
CD40L (CD154)	human/monkey	<i>in vitro</i> and <i>in vivo</i> blocking of CD40/CD40L signaling, IP, FC	5C8	BE0292	
CD44	mouse/human	<i>in vivo</i> CD44 neutralization	IM7	BE0039	
CD44	human	<i>in vivo</i> CD44 blockade in xenografts, <i>in vitro</i> CD44 blockade, WB, IF	Hermes-1	BE0262	
CD47	human	<i>in vitro</i> CD47 neutralization, <i>in vivo</i> CD47 neutralization in human tumor xenograft models or humanized mice, FC	B6H12	BE0019-1	
CD47	human/mouse/rat	<i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blockade, IF	MIAP410	BE0283	BP0283
CD47 (IAP)	mouse	<i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blockade, IF	MIAP301	BE0270	
CD69	mouse	<i>in vivo</i> down-regulation of CD69 expression, Functional assays	CD69.2.2	BE0330	
CD70	mouse	<i>in vivo</i> and <i>in vitro</i> CD70 blockade, FC	FR70	BE0022	
CD71 (TfR)	human	WB, IP, FC	5E9C11	BE0343	
CD71 (TfR1)	mouse	<i>in vivo</i> depletion of CD71+ cells	R17 217.1.3	BE0175	
CD71 (TfR1)	mouse	<i>in vivo</i> depletion of CD71+ cells, IF, IHC-F, WB	8D3	BE0329	
CD71 (TfR1)	rat/mouse	Targeted drug delivery to the brain, IHC-F, FC	OX-26	BE0331	
CD73	mouse	<i>in vivo</i> CD73 blockade	TY/23	BE0209	
CD80 (B7-1)	mouse	<i>in vivo</i> CD80 blockade, FC	16-10A1	BE0024	
CD86 (B7-2)	mouse	<i>in vivo</i> CD86 blockade, FC	GL-1	BE0025	
CD96	mouse	<i>in vivo</i> and <i>in vitro</i> CD96 blocking, FC	3.3	BE0337	
CD103	mouse	<i>in vivo</i> CD103 neutralization, IF, FC	M290	BE0026	
CD172a (SIRPα)	mouse	<i>in vivo</i> and <i>in vitro</i> SIRPα blocking, WB, IP, FC	P84	BE0322	
CD209b (SIGN-R1)	mouse	<i>in vivo</i> SIGN-R1 blockade, IHC-F, WB, FC	22D1	BE0220	
CD276 (B7-H3)	mouse	<i>in vivo</i> B7-H3 blockade, FC	MJ18	BE0124	
CD314 (NKG2D)	mouse	<i>in vivo</i> and <i>in vitro</i> NKG2D blockade, FC	CX5	BE0334	
CD326 (EpCAM)	mouse	IHC-F, IF, FC, WB	G8.8	BE0346	
c-Kit (CD117)	mouse	FC, IF, IHC	2B8	BE0280	
c-Kit (CD117)	mouse	<i>in vivo</i> mast cell depletion, <i>in vivo</i> c-Kit+ cell depletion, <i>in vitro</i> c-Kit neutralization, IP, FC	ACK2	BE0293	
c-myc	human	WB, ELISA, FC	9E10	BE0238	
CLEC9A (CD370)	mouse	<i>in vivo</i> Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC	7H11	BE0305	
CSF1R (CD115)	mouse	<i>in vivo</i> macrophage depletion, <i>in vitro</i> CSF-1R neutralization, <i>in vivo</i> monocyte depletion, FC	AFS98	BE0213	BP0213

癌症 - 临床前研究用体内抗体 (免疫治疗, 细胞与基因治疗)



如何选择: *InVivoMab* VS *InVivoPlus*

	<i>InVivoMab</i>	<i>InVivoPlus</i>
纯度	> 95%	> 95%
蛋白质聚集 ≤ 5% 验证		✓
不含叠氮化钠与载体蛋白	✓	✓
内毒素	< 2EU/mg	< 1EU/mg
WB, FC, ELISA等应用验证		✓
小鼠病原体检测 (无污染)		✓
大包装现货	✓	✓

靶标	反应种属	应用类型	克隆号	<i>InVivoMab</i>	<i>InVivoPlus</i>
CSF1R (CD115)	human	<i>in vitro</i> CSF1R neutralization, IHC-P, Functional assays, FC	2-4A5-4	BE0347	
CTLA-4 (CD152)	mouse	<i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization, FC	UC10-4F10-11	BE0032	BP0032
CTLA-4 (CD152)	mouse	<i>in vivo</i> and <i>in vitro</i> CTLA-4 neutralization	9H10	BE0131	BP0131
CTLA-4 (CD152)	mouse	<i>in vivo</i> CTLA-4 neutralization	9D9	BE0164	BP0164
CTLA-4 (CD152)	human	<i>in vitro</i> CTLA-4 neutralization, FC	BN13	BE0190	
DR5 (CD262)	mouse	<i>in vivo</i> and <i>in vitro</i> induction TRAIL-mediated apoptosis	MD5-1	BE0161	
EGFR	human	<i>in vitro</i> EGFR blockade, <i>in vivo</i> EGFR blockade in xenografts, WB, Functional assays	225	BE0278	
EGFR	human	<i>in vitro</i> EGFR blockade, <i>in vivo</i> EGFR blockade in xenografts, WB, Functional assays, IP, IHC-P, IF, FC	528	BE0279	
EphA2	human	IHC-P, IP, Functional assay	B2D6	BE0341	
E-Cadherin (CD324)	mouse	<i>in vivo</i> E-Cadherin neutralization, <i>in vitro</i> E-Cadherin neutralization, IF, IP, WB	DECMA-1	BE0352	
E-selectin (CD62E)	mouse	<i>in vivo</i> E-selectin blockade, <i>in vitro</i> E-selectin blockade, IHC-F	9A9	BE0294	
FasL (CD178)	mouse	<i>in vivo</i> and <i>in vitro</i> FasL blockade, Functional assay, IHC-P, FC	MFL3	BE0319	
FGL-1	mouse	<i>in vivo</i> and <i>in vitro</i> FGL-1 blockade, FC, IHC-P	177R4	BE0332	
Galectin-9	mouse	<i>in vivo</i> and <i>in vitro</i> Galectin-9 blockade	RG9-1	BE0218	
GITR	mouse	<i>in vivo</i> GITR stimulation	DTA-1	BE0063	BP0063
GM-CSF	mouse	<i>in vivo</i> and <i>in vitro</i> GM-CSF neutralization, FC	MPI-22E9	BE0259	
HER2 (neu)	human/rat	<i>in vivo</i> and <i>in vitro</i> HER2/neu inhibition, IP, IF, FC	7.16.4	BE0277	
ICOS	mouse	<i>in vivo</i> blocking of ICOS/ICOSL signaling, FC	7E.17G9	BE0059	
ICOSL (CD275)	mouse	<i>in vivo</i> ICOSL neutralization	HK5.3	BE0028	
IL-7Rα (CD127)	mouse	<i>in vivo</i> blocking of IL-7Rα signaling, FC	A7R34	BE0065	
IL-17F	mouse	<i>in vivo</i> IL-17F neutralization	MM17F8F5.1A9	BE0303	
IL-27 p28	mouse	<i>in vivo</i> and <i>in vitro</i> IL-27 p28 neutralization, FC	MM27.7B1	BE0326	
Jagged2	mouse	<i>in vivo</i> Jagged 2 neutralization	HMJ2-1	BE0125	
LAG-3	mouse	<i>in vivo</i> and <i>in vitro</i> LAG-3 neutralization, FC	C9B7W	BE0174	BP0174
LPAM-1 (Integrin α4β7)	mouse	<i>in vivo</i> Integrin α4β7 neutralization, FC	DATK32	BE0034	
LRP1 (CD91)	mouse/human/rat	WB, IF, IP	11H4	BE0333	
Ly6G	mouse	<i>in vivo</i> neutrophil depletion, <i>in vivo</i> MDSC depletion, IF, IHC-P, IHC-F, FC	1A8	BE0075-1	BP0075-1
Ly6G/Ly6C (Gr-1)	mouse	<i>in vivo</i> neutrophil depletion, IHC-P, IHC-F, IF, FC	NIMP-R14	BE0320	
Ly6G/Ly6C (Gr-1)	mouse	<i>in vivo</i> depletion of Gr-1+ myeloid cells, FC, IHC-P, IHC-F	RB6-8C5	BE0075	BP0076
MAGEC2 (CT10)	human	IHC-P, IF, WB	LX-CT10.5	BE0335	
MDR-1 (CD243)	human/monkey	<i>in vivo</i> MDR-1 blocking/depletion in xenogeneic murine tumor models, <i>in vitro</i> MDR-1 blocking, IHC-P	UIC2	BE0340	
MUC1 (CD227)	human	<i>in vivo</i> administration in mouse xenograft models, IHC-P, IF, <i>in vitro</i> cell cytotoxicity assay, WB	C595 (NCRC48)	BE0336	
NKG2A/C/E	mouse	<i>in vivo</i> and <i>in vitro</i> NKG2A blockade, IHC-F, FC	20D5	BE0321	
NKG2D	mouse	<i>in vivo</i> NKG2D blockade	HMG2D	BE0111	
PD-1 (CD279)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization	J43	BE0033-2	BP0033-3
PD-1 (CD279)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14	BE0146	BP0146
PD-1 (CD279)	human	<i>in vitro</i> PD-1 neutralization, <i>in vivo</i> PD-1 blockade in humanized mice	J116	BE0188	
PD-1 (CD279)	human	<i>in vivo</i> PD-1 blockade in humanized mice, FC	J110	BE0193	
PD-1 (CD279)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, FC, WB	29F.1A12	BE0273	BP0273
PD-L1 (B7-H1)	mouse	<i>in vivo</i> PD-L1 blockade, IF, IHC-F, FC	10F.9G2	BE0101	BP0101
PD-L1 (B7-H1)	human	<i>in vitro</i> PD-L1 blockade, Functional assays, IHC-F, FC	29E.2A3	BE0285	
PD-L2 (B7-DC)	mouse	<i>in vivo</i> and <i>in vitro</i> PD-L2 blockade, IHC-F, FC	TY25	BE0112	
RANKL (CD254)	mouse	<i>in vivo</i> RANKL blockade	IK22/5	BE0191	
TIM-1 (CD365)	mouse	<i>in vivo</i> TIM-1 neutralization	RMT1-10	BE0113	
TIM-1 (CD365)	mouse	<i>in vivo</i> and <i>in vitro</i> TIM-1 blockade	3D10	BE0314	
TIM-3 (CD366)	mouse	<i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC	RMT3-23	BE0115	BP0115
TNFα	mouse/rat/rabbit	<i>in vivo</i> TNFα neutralization, FC	TN3-19.12	BE0244	
VEGFR-2	mouse	<i>in vivo</i> blocking of VEGF/VEGFR-2 signaling, <i>in vitro</i> blocking of VEGFR signaling	DC101	BE0060	BP0061
VISTA	mouse	<i>in vivo</i> and <i>in vitro</i> blocking of VISTA signaling, FC	13F3	BE0310	BP0310
VLDL-R	mouse/rat/bovine	WB	IgG-6A6	BE0345	

2018年诺贝尔生理或医学奖得主 - James P. Allison

"我对 Bio X Cell 为我们提供的产品与服务完全满意。当有人问我的时候，我总是把 Bio X Cell 推荐给他们。我期待着再与 Bio X Cell 合作20年!"

25年来，科学家们一直信赖Bio X Cell，将其作为体内功能级抗体的首选来源。这体现在超过 19,000 篇同行评议的出版物中引用了Bio X Cell的产品。我们知道这个责任是最重要的，并继续致力于生产质量和一致性无与伦比的抗体，艾美捷将与Bio X Cell一道协助全球的合作伙伴，加快研究和发现！



Bio X Cell 中国区总代理：

艾美捷科技

400-6800-868

www.amyjet.com

